Bioxcel Therapeutics Inc Revenue Growth Rates (BTAI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Bioxcel Therapeutics Inc   (NASDAQ: BTAI)
 

BTAI's Revenue Growth by Quarter and Year

Bioxcel Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BTAI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0.18
1st Quarter March 0.21
FY 0.39





BTAI Revenue second quarter 2026 Y/Y Growth Comment
Bioxcel Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue rise of 51.67% year on year, to $ 0.18 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 58 other companies have achieved higher Revenue growth. While Bioxcel Therapeutics Inc ' s Revenue jump of 51.67% ranks overall at the positon no. 459 in the second quarter 2026.


BTAI Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -29.73 % -2.63 % 58.33 %
3rd Quarter September - -52.38 % -38.24 % 142.86 %
2nd Quarter June 51.67 % -89.09 % 139.13 % -
1st Quarter March 23.53 % -70.69 % 176.19 % -
FY   - -71.24 % 62.59 % -

Financial Statements
Bioxcel Therapeutics Inc 's second quarter 2026 Revenue $ 0.18 millions BTAI's Income Statement
Bioxcel Therapeutics Inc 's second quarter 2025 Revenue $ 0.12 millions Quarterly BTAI's Income Statement


BTAI Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 160 % 76.19 % 11.76 %
3rd Quarter September - -16.67 % -80.91 % -26.09 %
2nd Quarter June -13.33 % -29.41 % 89.66 % 119.05 %
1st Quarter March -19.23 % -54.05 % 52.63 % -12.5 %
FY (Year on Year)   - -71.24 % 62.59 % -


Back to BTAI Growth rate Comparisons >> Back to BTAI Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #119
Overall #459

Revenue Y/Y Growth Statistics
High Average Low
182.52 % 16.99 % -100 %
(Jun 30 2024)   (Dec 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #59
Healthcare Sector #119
Overall #459
Revenue Y/Y Growth Statistics
High Average Low
182.52 % 16.99 % -100 %
(Jun 30 2024)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bioxcel Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
575 % 47.41 % -100 %
(Dec 31 2020)  


BTAI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Bioxcel Therapeutics Inc disclosed drop in Revenue from the first quarter by -13.33% to $ 0.18 millions, from $ 0.21 millions achived in the previous reporting period.

But that's not important problem, as Bioxcel Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Revenue quarter on quarter growth. While Bioxcel Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3028.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #138
Healthcare Sector #391
Overall #3028
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #138
Healthcare Sector #391
Overall #3028
Revenue Q/Q Growth Statistics
High Average Low
575 % 47.41 % -100 %
(Dec 31 2020)  


BTAI's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Bioxcel Therapeutics Inc disclosed drop in Revenue from the first quarter by -13.33% to $ 0.18 millions, from $ 0.21 millions achived in the previous reporting period.

But that's not important problem, as Bioxcel Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Revenue quarter on quarter growth. While Bioxcel Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3028.


Bioxcel Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.74 $ 0.68 $ 0.64 $ 0.75 $ 0.87
Y / Y Revenue Growth (TTM) -14.52 % -63.28 % -71.67 % -66.96 % -63.88 %
Year on Year Revenue Growth Overall Ranking # 3617 # 1698 # 155 # 76 # 78
Seqeuential Revenue Change (TTM) 9.12 % 5.92 % -14.63 % -13.36 % -53.13 %
Seq. Revenue Growth (TTM) Overall Ranking # 3583 # 2838 # 2159 # 1852 # 300


Cumulative Revenue growth Comment
Bioxcel Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Bioxcel Therapeutics Inc 's annual Revenue drop would be -14.52% year on year to $1 millions.

In the Healthcare sector 512 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1698 to 3617.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 513
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
131.5 %
 0.46 %
-71.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 166
Sector # 501
S&P 500 # 3583
Cumulative Revenue growth Comment
Bioxcel Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Bioxcel Therapeutics Inc 's annual Revenue drop would be -14.52% year on year to $1 millions.

In the Healthcare sector 512 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1698 to 3617.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 166
Healthcare Sector # 513
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
131.5 %
0.46 %
-71.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 166
Sector # 501
S&P 500 # 3583




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BTAI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions


About Bioxcel Therapeutics Inc Revenue Growth Rates (BTAI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bioxcel Therapeutics Inc (CIK 1720893).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-095965
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bioxcel Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.